Yüklüyor......
Efficacy and tolerability of a low-dose, 2-week administration of sunitinib followed by a week rest (2/1 schedule) for metastatic renal cell carcinoma: a single center experience of six cases
BACKGROUND: Sunitinib, an oral multitarget tyrosine kinase inhibitor and standard first-line treatment for metastatic renal cell carcinoma (mRCC), is generally administered on a 6-week schedule (4 weeks on/2 weeks off). However, drug toxicity often leads to temporary treatment interruption, resultin...
Kaydedildi:
| Yayımlandı: | BMC Res Notes |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BioMed Central
2014
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4289163/ https://ncbi.nlm.nih.gov/pubmed/25471941 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-0500-7-872 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|